LWMH Vs Apixban after LSG for chemoprophylaxis

Published in Surgery

LWMH Vs Apixban after LSG for chemoprophylaxis
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Explore the Research

SpringerLink
SpringerLink SpringerLink

Comparison between low molecular weight heparin and apixaban (direct oral anticoagulant) in the prophylaxis against venous thromboembolism after laparoscopic sleeve gastrectomy - Obesity Surgery

Background Like any major operation, sleeve gastrectomy (SG) has its reported postoperative complications. Among them are venous thromboembolic complications (VTE) that may predispose to mortality. Despite the proven efficacy of the traditional anticoagulants, such as low molecular weight heparins (LMWHs) for VTE management, they have their limitations. Direct oral anticoagulants (DOACs) have been currently adopted for the management of VTE. We conducted this study to evaluate the efficacy and safety of apixaban against VTE after laparoscopic sleeve gastrectomy in comparison with LMWH. Methods This was a randomized controlled trial that included 100 adult patients who underwent SG and received LMWH (Group A) or apixaban (Group B) for VTE prophylaxis. We recorded and analyzed the postoperative events up to the 30th day after surgery. Results This study included Group A (n = 50) and Group B (n = 50). No VTE occurred in either group (0%). Postoperative bleeding was encountered in one patient of each group (2%). The follow-up venous Doppler study was unremarkable in the two groups. Conclusion Apixaban was shown to be comparable to LMWH for the prevention of VTE after LSG with similar efficacy and safety making it a promising alternative to LMWH in patients undergoing bariatric surgery.

We are excited to share our latest research:
"Comparison Between Low Molecular Weight Heparin and Apixaban in the Prophylaxis Against Venous Thromboembolism After Laparoscopic Sleeve Gastrectomy"

🔍 Key Findings:
✔️ No venous thromboembolism (VTE) events occurred in either group.
✔️ Apixaban was found to be as effective and safe as low molecular weight heparin (LMWH) for post-bariatric surgery VTE prophylaxis.
✔️ Similar rates of postoperative bleeding (2%) in both groups.
✔️ The study highlights the potential advantages of DOACs in bariatric surgery, including ease of administration and non-requirement for monitoring.

💡 Why This Matters:
Venous thromboembolism is a serious postoperative risk in bariatric surgery, and anticoagulation strategies remain a critical area of research. Our randomized controlled trial (RCT) suggests that apixaban could be a viable alternative to LMWH, offering a simpler and potentially more patient-friendly approach to VTE prophylaxis.

📖 Read the full article here: DOI: 10.1007/s11695-025-07721-y

🔬 We welcome discussions, insights, and collaborations on the use of DOACs in bariatric surgery! Have you encountered similar findings in your practice? Let’s talk!

#BariatricSurgery #VTE #Anticoagulation #Apixaban #LMWH #ObesitySurgery #DOACs #PatientSafety #SurgicalResearch

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Surgery
Life Sciences > Health Sciences > Surgery

Related Collections

With Collections, you can get published faster and increase your visibility.

The IFSO Collection

A collection of publications by members of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) and the American Society for Metabolic and Bariatric Surgery (ASMBS). **If you or one of your co-authors are members of IFSO or ASMBS, please submit your research to this topical collection for consideration in OBSU.**

Publishing Model: Hybrid

Deadline: Ongoing

Restrictive Bariatric Surgery in Focus: What’s Next for ESG and LSG?

This special issue explores the evolving landscape of restrictive bariatric procedures, with a focus on Endoscopic Sleeve Gastroplasty (ESG) and Laparoscopic Sleeve Gastrectomy (LSG). We welcome original research, reviews, videos and clinical perspectives on efficacy, safety, patient selection, and long-term outcomes. Contributions addressing the role of robotic-assisted restrictive bariatric surgery are also encouraged. Emphasis will be placed on innovations in technique, emerging technologies, and comparative studies. Papers that analyze postoperative complications, quality of life, or metabolic impact are particularly relevant. Submissions on training, cost-effectiveness, and access to care are also welcome. The goal is to capture the present and future of restrictive approaches in metabolic surgery. Join us in shaping this dynamic and rapidly advancing field

Publishing Model: Hybrid

Deadline: Ongoing